Mesothelin: an old solid tumor target for next generation drug modalities – a pipeline review
08 Sep 2023
ImmunotherapyAACR
BARCELONA, Spain I September 08, 2023 I La Merie Publishing released its newest product reviewing the pipeline of mesothelin-targeted immunotherapy candidates in R&D:
Mesothelin-Targeted Immunotherapy Pipeline Review
Target: Mesothelin
Product Category: Antibody; Cells; Vaccine
This product provides basic information on immunotherapy candidates in research and development targeting mesothelin.
This product consists of:
This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.
Mesothelin, is a 40 kD glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein overexpressed in many cancers, potentially involved in adhesion and metastasis. The well-known interacting partner of mesothelin is CA125/MUC16, a member of the mucin family of glycoproteins which is expressed in ovarian cancer and malignant mesothelioma Given the limited expression of mesothelin in normal tissues and overexpression in several tumor cells, mesothelin presents a desirable target for tumor-specific therapy.
Mesothelin expression has been identified in approximately 30% of cancers, including mesothelioma, ovarian, pancreatic, gastric, and non–small cell lung tumors, uterine malignancies as well as cholangiocarcinoma. In high grade ovarian cancer, mesothelin is overexpressed in 75% to 80% of patients. Normal expression of mesothelin is on mesothelial cells lining pleura, peritoneum, and pericardium. Low expression may be found on some other tissues, but anti-mesothelin antibodies or antibody-toxin conjugates have not shown much toxicity.
Although several first generation drug modalities used for targeting mesothelin eventually have failed in clinical studies, such as immunotoxins, thorium-targeted therapies, antibody-drug conjugates, chimeric antigen receptor T cells, natural killer cells as well as T-cell engaging antibodies, improved next generation versions of such drug modalities have been developed and are applied to novel immunotherapy candidates for mesothelin-expressing cancers.
The report “Mesothelin-Targeted Immunotherapy Pipeline Review” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/mesothelin-targeted-immunotherapy-pipeline-review/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
-Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.